EA
VIR icon

Evolution Advisers’s Vir Biotechnology VIR Stock Holding History

Evolution Advisers’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$0 Buy
+17
New +$162 ﹤0.01% 873

Other funds holding VIR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Evolution Advisers's VIR Position: Q2 2026 in Review

Evolution Advisers opened a new position in Vir Biotechnology (VIR) in Q2 2026: 17 shares worth $0. The stake represents ﹤0.01% of the portfolio and ranks #873 among its holdings.

237 funds tracked by Wall St. Rank hold VIR as of Q2 2026.

  • Evolution Advisers held 17 shares of Vir Biotechnology worth $0 as of Q2 2026.
  • Vir Biotechnology was a new Evolution Advisers position in Q2 2026.
  • Vir Biotechnology made up ﹤0.01% of Evolution Advisers's portfolio in Q2 2026, its #873 holding.
  • 237 funds tracked by Wall St. Rank held Vir Biotechnology as of Q2 2026.

Based on Evolution Advisers's 13F filing for Q2 2026, filed 31 Jul 2026.